Navigation Links
MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
Date:12/4/2008

Pivotal efficacy and safety studies meet primary endpoints

VALENCIA, Calif., Dec. 4/PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it has met the primary endpoints of its final two pivotal Phase 3 studies of AFRESATM, the company's ultra rapid acting, inhaled insulin product. The company expects to disclose more details of the top-line data from these studies in patients with type 1 and type 2 diabetes (studies 030 and 102) by mid-December.

"We are very pleased to announce the positive outcome of these, the last of our three pivotal Phase 3 studies. We look forward to presenting more complete data, including analyses of secondary endpoints, as soon as they are available, which are expected before the end of this year. AFRESA promises to be an important additional option for the treatment of patients with diabetes. Our next step is to finalize a new drug application for AFRESA, which we expect to submit to the FDA in early 2009," commented Dr. Peter Richardson, MannKind's chief scientific officer.

About Study 030

Study 030 compared the pulmonary safety of meal-time inhalation of AFRESA versus usual care in over 2000 patients with type 1 and type 2 diabetes. The study met its primary endpoint: after two years of treatment, no adverse effects were observed on patients' lungs in the AFRESA-treated group.

About Study 102

Study 102 compared the efficacy of meal-time AFRESA in combination with a long-acting basal insulin versus twice daily injections of pre-mixed insulin (a mixture of a rapid-acting insulin analog and intermediate-acting insulin). Study 102 met its primary endpoint, showing comparable improvements in HbA1c levels over 52 weeks between the two treatment groups.

<
'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. MannKind Announces New $350 Million Credit Facility
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports Third Quarter Financial Results
4. MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
5. MannKind to Present at the Cowen and Company Healthcare Conference
6. The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement
7. MannKind Corporation to Host Webcast Analyst Day September 16, 2008
8. MannKind Corporation Reports Third Quarter Financial Results
9. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
10. Haemacure Reports Third Quarter 2007 Results
11. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... California (PRWEB) March 28, 2015 Designers ... a new overlay entitled Scratches 5K from Pixel Film ... scratch effects to any media inside Final Cut Pro ... “StoryBoard Corporate saves time and is an effective tool ... using FCPX Overlay Scratches 5K's intuitive grunge overlays. Simply ...
(Date:3/28/2015)... March 28, 2015 Purity Products®, ... supplements announces the release of their revolutionary new ... in two randomized, double-blind, placebo-controlled clinical studies to ... and hip size. MuffinStop™ is a combination of ... Garcinia mangostana, fused together to create one of ...
(Date:3/28/2015)... LTW Cyber is an innovation hub ... the purpose of addressing the needs of the global ... own opportunities to grow while seeking collaborative opportunities with ... , Ventures in LTW Cyber focus on secure application ... identifying vulnerabilities and analyzing open source. As the ...
(Date:3/27/2015)... Wellness for Cancer–the first organization to ... the spa and wellness industry–has certified Hands On to ... or are living with cancer. Hands On , ... will be identified with a special Wellness for Cancer ... safe, therapeutic services for cancer patients. , Wellness for ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership with the ... for the 2015 and 2016 season. As the Storm’s exclusive ... athletic trainer for the team throughout each season. Tonight, the ... Cleveland Gladiators at Amalie Arena; the game starts at 7:30pm. ... as it gives us the opportunity, to provide health and ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3
... among people who have mild memory loss, and they can ... largest ever investigation into heart disease and stroke in those ... some of who had a MRI scan which could indicate ... at Wake Forest University now report on this sub-group, observing ...
... been at a loss when it comes to health issues. ... tobacco smoke for residents. Environmental tobacco smoke// (ETS, or passive ... - from exacerbation of asthma to eye irritation and even ... workplace and in public places. Researchers at the University of ...
... new study, researchers found that the treatment naltrexone is ... abuse. Researchers of alcohol often distinguish two patterns of ... drinking are saved up for the weekend and holidays, ... regularly and often with meals. The Anglo-Saxon pattern has ...
... new study, children of people with mood disorders who have ... own lives as well. The link is especially strong among ... who suffer from mood disorders themselves. ,Research has shown ... risk of committing suicide, but few studies have looked at ...
... they have observed that postmenopausal women who use estrogen are ... tissue change in the joints that causes pain in that ... over 40 years old. Experts estimate up to 70 percent ... conducted a study to see if estrogen plays a role ...
... a clot-buster injection may unclog a mechanical heart pump, ... from University Hospital in Germany,// felt that this is ... heart failure patients who receive left ventricular assist devices. ... pump-like device that is surgically implanted to maintain the ...
Cached Medicine News:
(Date:3/27/2015)... , March 27, 2015 XRpro ... for drug discovery and development services which features ... the pharmaceutical industry, announced financial results for the ... Timothy C.  Tyson, Chairman of XRpro Sciences commented, ... successfully transition from development stage to commercial stage ...
(Date:3/27/2015)... March 27, 2015 Report Details  ... leading ophthalmic drug companies  What does the ... ophthalmic industry ? Visiongain,s brand new report shows you ... prospects there. Our 242-page report provides 185 ... in the industry and the future market prospects. Our ...
(Date:3/27/2015)... DALLAS , March 27, 2015 ... Market by Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation ... ICE, X-ray)) & Indication (AF, VT, WPW) - Global ... Market is expected to reach around ~$4.73 Billion by ... forecast period 2014 to 2019. Browse ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... Genetics, a global leader in genomic services, announced today ... Generation Sequencing System as well as received the first ... been an early adapter of Illumina systems since late ... Provider. A team of scientists routinely process libraries for ...
... 25 QBC Diagnostics was awarded one of the largest ... agreed to install QBC STAR hematology analyzers on surface ships ... a 9-parameter complete blood count through its patented dry hematology ... this technology, as well as the unit,s small footprint and ...
Cached Medicine Technology:Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities 2
Richardson Retractor...
A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant....
... The Advanta™ PTFE facial implant is ... intended for augmentation or repair of ... This product is available in sheets ... Advanta™ PTFE round facial implant strands ...
Chin Implants are used for cosmetic augmentation, repairing trauma related injuries and genetic deficiencies. They are inserted through an incision in the mouth below the incisor teeth or through an ...
Medicine Products: